Interestingly, experimental evidence shows that the expression of BCL-2 is higher in ETP-ALL than in more mature T-ALL, thus showing resemblances to AML, and offering a druggable therapeutic target [42, 43]. The gene discussed is BCL2; the disease is acute lymphoblastic leukemia.